Shoeb Qureshi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shoeb Qureshi has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
A. M. Al-Bekairi
1 shared publicationAbdulaziz A. Al-Yahya
1 shared publicationAbdulhakeem A. Al-Majed
Department of Pharmacology, College of Pharmacy, King Saud University, PO Box 2457, Riyadh 11451, Saudi Arabia
1 shared publicationAbdullah Foraih Al-Anazi
Department of Pediatric Emergency, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
1 shared publicationKhalida Javaid
Department of Obstetrics and Gynecology, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia
1 shared publicationOthman A. Al-Shabanah
1 shared publication
Latest Publications
- Open Access
- 1 January 2011
- Published by Manuscript Technomedia LLP in Journal of Natural Science, Biology and Medicine
- Vol. 2 (2) , 154-63
Preventive effects of phytoestrogens against postmenopausal osteoporosis as compared to the available therapeutic choices: An overview
Estrogen deficiency is a major risk factor for osteoporosis in postmenopausal women. Although hormone replacement therapy (HRT) has been rampantly used to recompense for the bone loss, but the procedure is coupled with severe adverse effects. Hence, there is a boost in the production of newer synthetic products to ward off the effects of menopause-related osteoporosis. As of today, there are several prescription products available for the treatment of postmenopause osteoporosis; most of these are estrogenic agents and combination products. Nevertheless, in view of the lack of effect and/or toxicity of these products, majority of the postmenopausal women are now fascinated by highly publicized natural products. This is an offshoot of the generalized consensus that these products are more effective and free from any adverse effects. Recently, certain plant-derived natural products, mostly phytoestrogens (isoflavones, lignans, coumestanes, stilbenes, flavonoids) and many more novel estrogen-like compounds in plants have been immensely used to prevent menopause-related depletion in bone mineral density (BMD). Although, a number of papers are published on menopause-related general symptoms, sexual dysfunction, cardiovascular diseases, Alzheimer's disease, diabetes, colon, and breast cancers, there is paucity of literature on the accompanying osteoporosis and its treatment. In view of the controversies on synthetic hormones and drugs and drift of a major population of patients toward natural drugs, it was found worthwhile to investigate if these drugs are suitable to be used in the treatment of postmenopausal osteoporosis. Preparation of this paper is an attempt to review the (a) epidemiology of postmenopausal osteoporosis, (b) treatment modalities of postmenopausal osteoporosis by hormones and synthetic drugs and the associated drawbacks and adverse effects, and (c) prevention and treatment of postmenopausal osteoporosis by phytoestrogens, their drawbacks and toxicity. It is apparent that both the categories of treatment are useful and both have adverse effects, but the plant products are nonscientific and hence are not advised to be used till more studies are undertaken to ensure that the benefits clearly outweigh the risk, in addition to recognition by Food and Drug Administration.
- 1 January 2011
- Published by Manuscript Technomedia LLP in Journal of Natural Science, Biology and Medicine
- Vol. 2 (2) , 154-63
Open AccessPreventive effects of phytoestrogens against postmenopausal osteoporosis as compared to the available therapeutic choices: An overview
Estrogen deficiency is a major risk factor for osteoporosis in postmenopausal women. Although hormone replacement therapy (HRT) has been rampantly used to recompense for the bone loss, but the procedure is coupled with severe adverse effects. Hence, there is a boost in the production of newer synthetic products to ward off the effects of menopause-related osteoporosis. As of today, there are several prescription products available for the treatment of postmenopause osteoporosis; most of these are estrogenic agents and combination products. Nevertheless, in view of the lack of effect and/or toxicity of these products, majority of the postmenopausal women are now fascinated by highly publicized natural products. This is an offshoot of the generalized consensus that these products are more effective and free from any adverse effects. Recently, certain plant-derived natural products, mostly phytoestrogens (isoflavones, lignans, coumestanes, stilbenes, flavonoids) and many more novel estrogen-like compounds in plants have been immensely used to prevent menopause-related depletion in bone mineral density (BMD). Although, a number of papers are published on menopause-related general symptoms, sexual dysfunction, cardiovascular diseases, Alzheimer's disease, diabetes, colon, and breast cancers, there is paucity of literature on the accompanying osteoporosis and its treatment. In view of the controversies on synthetic hormones and drugs and drift of a major population of patients toward natural drugs, it was found worthwhile to investigate if these drugs are suitable to be used in the treatment of postmenopausal osteoporosis. Preparation of this paper is an attempt to review the (a) epidemiology of postmenopausal osteoporosis, (b) treatment modalities of postmenopausal osteoporosis by hormones and synthetic drugs and the associated drawbacks and adverse effects, and (c) prevention and treatment of postmenopausal osteoporosis by phytoestrogens, their drawbacks and toxicity. It is apparent that both the categories of treatment are useful and both have adverse effects, but the plant products are nonscientific and hence are not advised to be used till more studies are undertaken to ensure that the benefits clearly outweigh the risk, in addition to recognition by Food and Drug Administration.
- Open Access
- 1 July 2006
- Published by Medknow in Asian Journal of Andrology
- Vol. 8 (4) , 469-476
Reproductive, cytological and biochemical toxicity of Yohimbe in male swiss albino mice
AJA publishes new findings in basic and clinical (including modern, traditional and epidemiological) research on Andrology.
- 1 July 2006
- Published by Medknow in Asian Journal of Andrology
- Vol. 8 (4) , 469-476
Open AccessReproductive, cytological and biochemical toxicity of Yohimbe in male swiss albino mice
AJA publishes new findings in basic and clinical (including modern, traditional and epidemiological) research on Andrology.